Product Development Pipeline

2007

September

Product Development PipelineSeptember 2007

Cardiovascular Cardiovascular projects& Metabolic

256073 high affinity nicotinic acid receptor dyslipidaemia I(HM74A) agonist813893 factor Xa inhibitor prevention of stroke in atrial fibrillation Irilapladib†Lp-PLA2 inhibitor atherosclerosis I681323 p38 kinase inhibitor atherosclerosis (also chronic obstructive pulmonary disease – llCOPD, neuropathic pain & rheumatoid arthritis)856553 p38 kinase inhibitoratherosclerosis (also rheumatoid arthritis & COPD)lldarapladib†Lp-PLA2 inhibitor atherosclerosis ll/III

Coreg CR

†+ACE inhibitor beta blocker + angiotensin converting hypertension – fixed dose combination III N/Aenzyme inhibitor

Volibris

(ambrisentan)†endothelin A antagonist pulmonary arterial hypertension Submitted S:Mar07 N/A

Arixtra

synthetic factor Xa inhibitor treatment of acute coronary syndrome Approved A:Aug07 AL:Feb07&Sep07

Metabolic projects

189075†sodium dependent glucose transport (SGLT2) obesity Iinhibitor376501 PPAR gamma partial agonist type 2 diabetes I189075†SGLT2 inhibitor type 2 diabetes ll

Syncria

(albiglutide)†glucagon-like peptide 1 agonist type 2 diabetes II

Avandamet XR

PPAR gamma agonist + metformin type 2 diabetes – extended release III N/A 2008*

Avandia

PPAR gamma agonist atherosclerosis in type 2 diabetes IIl

Avandia

PPAR gamma agonist prevention of diabetes III N/A 2008*

Avandia

+simvastatin PPAR gamma agonist + statin type 2 diabetes III N/A 2008*

Avandia

PPAR gamma agonist prevention of disease progression Submitted 2008* S:Feb07

Infectious Diseases

580416ribosome inhibitortreatment of bacterial infectionsl945237topoisomerase ll inhibitortreatment of bacterial infectionslfarglitazar PPAR gamma agonist hepatic fibrosis IIsitamaquine 8-aminoquinolinetreatment of visceral leishmaniasis II N/Atafenoquine†8-aminoquinoline

Plasmodium vivax

malaria II

Dacart

(chlorproguanil, antifolate + artemisinin treatment of uncomplicated malaria IIl 2008 N/Adapsone + artesunate)†

Altabax/Altargo

topical pleuromutilin bacterial skin infections Approved A:May07 A:Apr07

Musculoskeletal,

1827771interleukin 1 antagonistrheumatoid arthritisl

Inflammation,

221149 oxytocin antagonist threatened pre-term labour I

Gastrointestinal

315234 monoclonal antibody rheumatoid arthritis I

& Urology

768974†parathyroid hormone agonist osteoporosis I971086androgen modulatorsarcopaenialpazopanibvascular endothelial growth factor (VEGF) age-related macular degeneration (also cancer indications)ltyrosine kinase inhibitor232802 3G-selective oestrogen receptor modulator treatment of menopausal symptoms ll274150 selective iNOS inhibitor rheumatoid arthritis (also migraine) II681323 p38 kinase inhibitor (oral) rheumatoid arthritis (also atherosclerosis, COPD II&neuropathic pain)856553 p38 kinase inhibitor (oral) rheumatoid arthritis (also atherosclerosis & COPD) II876008†corticotrophin releasing factor (CRF1) antagonist irritable bowel syndrome (also depression & anxiety) IIofatumumab†human monoclonal antibodyrheumatoid arthritis (also cancer indications)llronacaleret (751689)†calcium antagonistosteoporosis & fracture healingllsolabegron beta3 adrenergic agonist irritable bowel syndrome IIsolabegron beta3 adrenergic agonist overactive bladder II

Avodart

5-alpha reductase inhibitor reduction in the risk of prostate cancer III

Avodart

+alpha blocker 5-alpha reductase inhibitor + alpha blocker benign prostatic hyperplasia – fixed dose combination IIIbelimumab†anti-B lymphocyte stimulator monoclonal systemic lupus erythematosus IIIantibody

Bosatria

(mepolizumab) anti-IL5 monoclonal antibody hypereosinophilic syndrome (also severe asthma & nasalIII20082008polyposis)

Entereg/Entrareg

†peripheral mu-opioid antagonist opioid-induced bowel dysfunction III

Entereg/Entrareg

†peripheral mu-opioid antagonist post operative ileus Approvable AL:Jul05&Nov06

Neurosciences

163090 5HT1 antagonist depression & anxiety I239512 histamine H3 antagonist dementia I249320monoclonal antibodyneuronal injuryl561679†CRF1 antagonist depression & anxiety I588045 5HT1 antagonist depression & anxiety I598809 dopamine D3 antagonist drug dependency I618334dopamine D3 antagonistdrug dependencyl729327 AMPA receptor modulator schizophrenia I933776monoclonal antibodyAlzheimer’s diseasel1014802sodium channel inhibitorbipolar disorderl1018921type 1 glycine transport inhibitorschizophrenialorvepitant (823296) NK1 antagonist depression & anxiety I189254histamine H3 antagonistnarcolepsyll274150 selective iNOS inhibitor migraine (also rheumatoid arthritis) II372475†triple (5HT/noradrenaline/dopamine) re-uptake depression IIinhibitor468816 glycine antagonist smoking cessation II649868†orexin antagonist sleep disorders II681323 p38 kinase inhibitor neuropathic pain (also atherosclerosis, COPD & rheumatoidIIarthritis)742457 5HT6 antagonist dementia II773812 mixed 5HT/dopaminergic antagonist schizophrenia II842166 non-cannabinoid CB2 agonist inflammatory pain II876008†CRF1 antagonist depression & anxiety (also irritable bowel syndrome) IIcasopitant NK1 antagonist depression & anxiety (also as

Rezonic/Zunrisa

for IIchemotherapy-induced & postoperative nausea & vomiting)1838262 (XP13512)†voltage-gated calcium channel modulatorneuropathic painllfirategrast (683699)†dual alpha4 integrin antagonist (VLA4) multiple sclerosis II1838262 (XP13512)†voltage-gated calcium channel modulatorrestless legs syndromelllN/A2008

Lamictal XR

sodium channel inhibitor epilepsy – partial generalised tonic-clonic seizures, once-dailyIIIN/A2008rosiglitazone XRPPAR gamma agonist Alzheimer's disease IIIgepirone ER†5HT1a agonist major depressive disorder, once-daily Submitted S:May07

Lamictal XR

sodium channel inhibitor epilepsy – partial seizures, once-daily Approvable N/A AL:Sep07

ReQuip

extended release non-ergot dopamine agonist restless legs syndrome Approvable N/A AL:Aug07

Trexima

†5HT1 agonist + naproxen migraine – fixed dose combination Approvable N/A AL:Jun06&Aug07

ReQuip Modutab/XL

24 hour†non-ergot dopamine agonist Parkinson’s disease – once-daily controlled release Approved A:Mar07 S:Feb07formulation

Oncology

690693AKT kinase inhibitorcancerl923295†centromere-associated protein E (CENP-E)cancerlinhibitorpazopanib VEGF tyrosine kinase inhibitormetastatic colorectal cancer (in combination with other Itreatment regimens)iboctadekin†+rituximablL18 immunomodulator + anti-CD20 non-Hodgkin’s lymphomalmonoclonal antibodytotrombopag (559448)†thrombopoietin agonist thrombocytopaenia IpazopanibVEGF tyrosine kinase inhibitornon-small cell lung cancer,adjuvant therapyllpazopanibVEGF tyrosine kinase inhibitorovarian cancer,first-line therapyllpazopanibVEGF tyrosine kinase inhibitorsarcomallpazopanib +

Tykerb

VEGF tyrosine kinase inhibitor + ErbB-2 and metastatic breast cancer IIepidermal growth factor receptor (EGFR)dual kinase inhibitorpazopanib +

Tykerb

VEGF tyrosine kinase inhibitor + ErbB-2 and other cancers IIEGFR dual kinase inhibitor

Promacta/Revolade

†thrombopoietin agonist chemotherapy-induced thrombocytopaenia II

Promacta/Revolade

†thrombopoietin agonist hepatitis C II

Tykerb/Tyverb

ErbB-2 and EGFR dual kinase inhibitorhead & neck squamous cell carcinomas (unresectable disease)ll

Tykerb/Tyverb

ErbB-2 and EGFR dual kinase inhibitorrefractory inflammatory breast cancerll

Hycamtin

topoisomerase I inhibitor ovarian cancer, first-line therapy IIIofatumumab†human monoclonal antibody refractory chronic lymphocytic leukaemia (also rheumatoid IIIarthritis)ofatumumab†human monoclonal antibodyrefractory follicular lymphoma (also rheumatoid arthritis)lllpazopanib VEGF tyrosine kinase inhibitor renal cell cancer III

Promacta/Revolade

†thrombopoietin agonist long-term idiopathic thrombocytopaenic purpura III2008

Promacta/Revolade

†thrombopoietin agonist short-term idiopathic thrombocytopaenic purpura III20082007/08

Rezonic/Zunrisa

(casopitant)NK1 antagonistchemotherapy-induced & postoperative nausea & vomitingIII20082008(also depression & anxiety)

Tykerb/Tyverb

ErbB-2 and EGFR dual kinase inhibitor breast cancer, adjuvant therapy III

Tykerb/Tyverb

ErbB-2 and EGFR dual kinase inhibitorbreast cancer brain metastaseslll

Tykerb/Tyverb

ErbB-2 and EGFR dual kinase inhibitor breast cancer, first-line therapy III

Tykerb/Tyverb

ErbB-2 and EGFR dual kinase inhibitor head & neck squamous cell carcinomas (resectable disease) III

Hycamtin

topoisomerase I inhibitor small cell lung cancer, second-line therapy – oral formulation SubmittedS:May07S:Apr07

Arranon/Atriance

guanine arabinoside prodrug acute lymphoblastic leukaemia & lymphomas Approved A:Aug07 A:Oct05

Tykerb/Tyverb

ErbB-2 and EGFR dual kinase inhibitor refractory breast cancer Approved S:Oct06 A:Mar07

Respiratory

256066 PDE IV inhibitor (inhaled) COPD I656933interleukin 8 antagonistcystic fibrosisl961081†muscarinic antagonist, beta2 agonist COPD I159797†long-acting beta2 agonist COPD, also COPD & asthma in combination with a IIglucocorticoid agonist159802†long-acting beta2 agonist COPD, also COPD & asthma in combination with a IIglucocorticoid agonist233705 muscarinic acetylcholine antagonist COPD II256066 PDE IV inhibitor (inhaled) asthma II256066 PDE IV inhibitor (intranasal) allergic rhinitis II573719 muscarinic acetylcholine antagonist COPD Il642444†long-acting beta2 agonist COPD, also COPD & asthma in combination with a IIglucocorticoid agonist679586 monoclonal antibody severe asthma Il681323 p38 kinase inhibitor (oral) COPD (also atherosclerosis, neuropathic pain & IIrheumatoid arthritis)685698 glucocorticoid agonist asthma, also COPD & asthma in combination with a IIlong-acting beta2 agonist (also as

Avamys/Veramyst

forallergic rhinitis)784568 glucocorticoid agonist (intranasal) allergic rhinitis II856553 p38 kinase inhibitor (oral) COPD (also atherosclerosis & rheumatoid arthritis) II870086 novel glucocorticoid agonist asthma IImepolizumab anti-IL5 monoclonal antibody severe asthma & nasal polyposis (also hypereosinophilic IIsyndrome)

Seretide/Advair

beta2 agonist/inhaled corticosteroid COPD – mortality claim / extended useSubmitted/ S:Sep06/ S:Oct06ApprovedA:Jul07

Avamys/Veramyst

glucocorticoid agonist allergic rhinitis Approved S:Jul06 A:Apr07

Paediatric Vaccines

Hib-MenCY-TT conjugated

Neisseria meningitis

groups C & Y disease & III

Haemophilus influenzae

type b disease prophylaxisMenACWY-TT conjugated

Neisseria meningitis

groups A, C, W & Y disease prophylaxisIIl

Synflorix

conjugated

Streptococcus pneumoniae &

non-typeable

Haemophilus

lll 2007

influenzae

disease prophylaxis for children

Globorix

conjugated diptheria, tetanus, pertussis, hepatitis B,

Haemophilus

Submitted S:Mar07

influenzae

type b disease,

Neisseria meningitis

groupsA&Cdisease prophylaxis

Infanrix-IPV/Kinrix

subunit-inactivated diptheria, tetanus, pertussis + poliomyelitis prophylaxisSubmittedS:Apr07(booster-5th dose)

Rotarix

†live attenuated (oral) rotavirus-induced gastroenteritis prophylaxis Approved A:Feb06 S:Jun07

Other Vaccines

Cytomegalovirusrecombinantcytomegalovirus infection prophylaxislHIVrecombinantHIV infection prophylaxis l

S. pneumoniae

adultrecombinant-conjugated

Streptococcus pneumoniae

disease prophylaxis lDengue fever attenuated tetravalent Dengue fever prophylaxis llEpstein-Barr virus†recombinant EBV infection prophylaxis llHepatitis E virus†recombinant hepatitis E prophylaxis ll

Mosquirix

recombinant malaria prophylaxis llTuberculosisrecombinant tuberculosis prophylaxis IIVaricella Zoster virus recombinant Varicella Zoster prevention IINew generation flu vaccine inactivated split – trivalent seasonal influenza prophylaxis for the elderly III

Simplirix

recombinant genital herpes prophylaxis lllFlu pandemicH5N1 inactivated split – monovalentpandemic influenza prophylaxisSubmittedS:Feb07Flu pre-pandemic H5N1 inactivated split – monovalent pandemic influenza prophylaxis Submitted S:Jan07

Cervarix

†recombinant human papilloma virus infection prophylaxis Approved A:Sep07 S:Mar07

Daronrix

inactivated whole - monovalent pandemic influenza prophylaxis ApprovedA:Mar07

Pharmaccines

MAGE-A3recombinanttreatment of melanomallMAGE-A3recombinant treatment of non-small cell lung cancer lll

Ther

apeuti

c ar

aCompoundT

ypeIndi

cati

onPhaseE

stimatedsubmi

on date

sMAANDA

/BL

Brand names appearing in italics are trademarks either owned by and/or licensed to GlaxoSmithKline or associated companies, with theexception of

Entereg

, a trademark of Adolor Corporation in the USA, which is used in certain countries under licence by the Group.

Key

(v)VaccineMAAMarketing authorisation application (Europe) (p)PharmaccineNDANew drug application (USA) †In-license or other alliance relationship with third partyPhase IEvaluation of clinical pharmacology, usually conducted in volunteers*Subject to completion of ongoing regulatory discussions.Phase IIDetermination of dose and initial evaluation of efficacy,SDate of first submissionconducted in a small number of patientsADate of first regulatory approval (for MAA, this is the first EUPhase IIILarge comparative study (compound versus placebo approval letter)and/or established treatment) in patients to establishclinical benefit and safety.ALApprovable letter indicates that ultimately approval can begiven subject to resolution of outstanding queries

CAUT

RY S

TATEME

NT REG

G F

ORWA

RD-LO

ING INF

RMAT

ION

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of1995, the company cautions investors that any forward-looking statements orprojections made by the company, including those made in this document, are subjectto risks and uncertainties that may cause actual results to differ materially from thoseprojected.Continued development of commercially viable new products is critical to the Group’sability to replace sales of older products that decline upon expiration of exclusiverights, and to increase overall sales. Developing new products is a costly, lengthy anduncertain process. A new product candidate can fail at any stage of the process, andone or more late-stage product candidates could fail to receive regulatory approval.New product candidates may appear promising in development but, after significantinvestments, fail to reach the market or have only limited commercial success as a resultof efficacy or safety concerns, inability to obtain necessary regulatory approvals,difficulty or excessive costs to manufacture or infringement of patents or otherintellectual property rights of others or inability to differentiate the productadequately from those with which it competes.Other factors that may affect the Group's operations are described under 'Risk Factors'in the Operating and Financial Review and Prospects in the company's Annual Reporton Form 20-F for 2006.

Estimated submission dates are only disclosed where they are within 12 months of the date of the chart. This date represents the most likelyyear of submission where it is considered that there is a reasonably high probability of successfully meeting the date assuming the clinicaldata meets the expected end-points of the clinical trials.

This document outlines GlaxoSmithKline’s drug developmentportfolio. The content of the drug development portfolio willchange over time as new compounds progress from discoveryto development and from development to the market. Owingto the nature of the drug development process, many of thesecompounds, especially those in early stages of investigation,may be terminated as they progress through development. Forcompetitive reasons, new projects in pre-clinical developmenthave not been disclosed and some project types may not havebeen identified.

Product Development PipelineSeptember 2007

Phase IPhase IIPhase IIIFiled/Approved681323856553darapladib†189075†

Syncria

(albiglutide)†farglitazarsitamaquinetafenoquine†232802274150876008†ronacaleret (751689)†ofatumumab†solabegron189254372475†468816649868†742457773812842166casopitant1838262 (XP13512)†firategrast (683699)†pazopanibpazopanib +

TykerbPromacta/Revolade

†

Tykerb/Tyverb

159797†159802†233705256066573719642444†679586685698784568870086mepolizumabDengue fever (v)Epstein-Barr virus (v)†Hepatitis E (v)†

Mosquirix

(v)Tuberculosis (v)Varicella Zoster (v)MAGE-A3 (p)

Coreg CR

†+ACE Inhibitor

Avandamet XR Avandia Avandia +

simvastatin

Dacart

(chlorproguanil, dapsone+artesunate)†

Avodart Avodart

+alpha blockerbelimumab†

Bosatria

(mepolizumab)

Entereg/Entrareg

†1838262 (XP13512)†

Lamictal XR

rosiglitazone XR

Hycamtin

ofatumumab†pazopanib

Promacta/Revolade

†

Rezonic/Zunrisa

(casopitant)

Tykerb/Tyverb

MenACWY-TT (v)Hib-MenCY-TT(v)

Synflorix (v)

New generation flu vaccine (v)

Simplirix

(v)MAGE-A3 (p)

Volibris

(ambrisentan)†

Avandia Arixtra Altabax/AltargoEntereg/Entrareg

†gepirone ER†

Lamictal XRReQuip extended releaseTrexima

†

ReQuip Modutab

/XL 24 hour

Hycamtin Arranon/AtrianceTykerb/TyverbSeretide/Advair Avamys/Allermist Globorix

(v)

Infranrix-IPV/Kinrix (v)Rotarix

(v)†Flu pandemic (v)Flu pre-pandemic (v)

Cervarix

(v)†Daronrix (v)256073813893rilapladib†189075†3765015804169452371827771221149315234768974†971086pazopanib163090239512249320561679†588045598809618334729327933176orvepitant (823296)10148021018921690693923295†iboctadekin†+rituximabtotrombopag (559448)†256066656933961081†cytomegalovirus (v)HIV (v)

S. pneumoniae

adult (v)